These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 12424713

  • 21. A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin.
    Kamar N, Guitard J, Ribes D, Esposito L, Rostaing L.
    Exp Clin Transplant; 2008 Dec; 6(4):271-5. PubMed ID: 19338488
    [Abstract] [Full Text] [Related]

  • 22. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
    Dieterich DT, Wasserman R, Bräu N, Hassanein TI, Bini EJ, Bowers PJ, Sulkowski MS.
    Am J Gastroenterol; 2003 Nov; 98(11):2491-9. PubMed ID: 14638354
    [Abstract] [Full Text] [Related]

  • 23. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM, Sheen IS, Liaw YF.
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [Abstract] [Full Text] [Related]

  • 24. Adiponectin: a new independent predictor of liver steatosis and response to IFN-alpha treatment in chronic hepatitis C.
    Zografos TA, Liaskos C, Rigopoulou EI, Togousidis E, Makaritsis K, Germenis A, Dalekos GN.
    Am J Gastroenterol; 2008 Mar; 103(3):605-14. PubMed ID: 18190648
    [Abstract] [Full Text] [Related]

  • 25. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection.
    Neff GW, O'Brien CB, Nery J, Shire NJ, Nishida S, delaGarza J, Montalbano M, Safdar K, Ruiz P, Rideman E, Gascon JA, Tzakis AG, Madariaga J, Rudich SM.
    Liver Transpl; 2004 Dec; 10(12):1497-503. PubMed ID: 15558835
    [Abstract] [Full Text] [Related]

  • 26. Effect of interferon-alpha-based antiviral therapy on hepatitis C virus-associated glomerulonephritis: a meta-analysis.
    Feng B, Eknoyan G, Guo ZS, Jadoul M, Rao HY, Zhang W, Wei L.
    Nephrol Dial Transplant; 2012 Feb; 27(2):640-6. PubMed ID: 21558431
    [Abstract] [Full Text] [Related]

  • 27. [Acute renal insufficiency in renal transplants treated with interferon-alpha for chronic hepatitis C].
    Rostaing L, Modesto A, Baron E, Cisterne JM, Chabannier MH, Tkaczuk J, Durand D, Suc JM.
    Nephrologie; 1996 Feb; 17(4):247-54. PubMed ID: 8768457
    [Abstract] [Full Text] [Related]

  • 28. Ribavirin and interferon for recurrent posttransplantation HCV infection: to treat or not to treat?
    McHutchison JG.
    Hepatology; 1997 Aug; 26(2):505-6. PubMed ID: 9252167
    [No Abstract] [Full Text] [Related]

  • 29. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function.
    Kamar N, Chatelut E, Manolis E, Lafont T, Izopet J, Rostaing L.
    Am J Kidney Dis; 2004 Jan; 43(1):140-6. PubMed ID: 14712437
    [Abstract] [Full Text] [Related]

  • 30. Combination therapy for hepatitis C.
    TreatmentUpdate; 1998 Mar; 10(1):2-3. PubMed ID: 11365430
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effect of drug-induced hyperuricaemia on renal function in Nigerians with pulmonary tuberculosis.
    Adebisi SA, Oluboyo PO, Okesina AB.
    Afr J Med Med Sci; 2000 Mar; 29(3-4):297-300. PubMed ID: 11714010
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Concentration of b2-microglobulin and percentage of CD4 lymphocytes in peripheral blood in patients with chronic HCV infection during IFN-a therapy.
    ŁApiński TW, Kot A, Prokopowicz D.
    Med Sci Monit; 2002 Jul; 8(7):CR538-42. PubMed ID: 12118205
    [Abstract] [Full Text] [Related]

  • 40. Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry.
    Alam I, Stainbrook T, Cecil B, Kistler KD.
    Aliment Pharmacol Ther; 2010 Aug; 32(4):535-42. PubMed ID: 20500732
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.